Nov 08 2022
Proposition 122 legalizes the personal use and possession of several hallucinogenic/entheogenic plants and fungi for those 21 and older. Those include:
Nov 08 2022
Question 4 amends the Maryland Constitution to add a new article, Article XX, which authorizes individuals 21 years of age or older to use and possess marijuana for all uses. The initiative also directs the Maryland General Assembly to “provide for the use, distribution, possession, regulation, and taxation of cannabis within the state”, which they have already done.
During the 2022 legislative session the state legislature passed legislation to implement legalization if the initiative were to pass, including a system to regulate licensed retail outlets. The proposal sets the legal possession limit at 1.5 ounces and two plants.
Continue reading
Nov 07 2022
The study, titled Use of Medical Cannabis in Patients with Gilles de la Tourette’s Syndrome in a Real-World Setting, was conducted by researchers at Tel-Aviv University.
“Tourette’s syndrome (TS) is a neurodevelopmental disorder characterized by vocal and motor tics and other comorbidities”, states the study. “Clinical recommendations for the use of medical cannabis are established, yet further guidance is needed.” The aim of this study “was to describe the experience of patients with TS with medical cannabis.”
Continue reading
Nov 07 2022
“Cannabidiol (CBD) has been suggested as a potential therapy for inflammatory and fibrotic diseases”, states the study’s abstract. “Cannabidiol was demonstrated to reduce alcohol-induced liver inflammation and steatosis but its specific activity on the fibrotic process was not investigated.”
For this study “the antifibrotic effects of cannabidiol in the skin were analysed in vitro using NIH-3T3 fibroblasts and human dermal fibroblasts and in vivo using the bleomycin-induced model of skin fibrosis.”
Continue reading
Nov 05 2022
Fibromyalgia is a complex pain-focused syndrome, and previous studies “showed that Cannabis is efficacious in promoting sleep, deepening and lengthening the sleep cycle, and good pain relief (compared to SSRIs and SNRIs)”, states the study’s abstract. This new study “aimed to use the World Health Organization Quality of Life Bref questionnaire (WhoQoL-bref) to characterize the impact of Cannabis Treatment initiation on the quality of life in women suffering from treatment-resistant fibromyalgia.”
The study was a prospective cohort study involving women aged 18-70 years old diagnosed with fibromyalgia who have “exhausted pharmacological fibromyalgia treatment, and started Cannabis treatment.” Pregnant women were excluded.
Continue reading
Nov 04 2022
If voters in Maryland, Arkansas, South Dakota, North Dakota and Missouri decide that marijuana should in fact be legal for everyone 21 and older, for any purpose, it will bring the total number of legal marijuana states in the U.S. to 24, just one shy of half the nation. What makes these five efforts of particular interest to politicos is that most are traditionally conservative states, allowing for an opportunity to see if marijuana reform has truly become a bipartisan issue (something reflected in recent nationwide polling).
Of the five legalization initiatives on Tuesday’s ballot, all but one – South Dakota – would authorize licensed marijuana retail outlets to sell marijuana, marijuana concentrates and marijuana edibles to those 21 and older. South Dakota would only legalize possession and cultivation, while establishing no specific guidelines for marijuana stores.
Continue reading
Nov 03 2022
For the study researchers examined the relationship between current and/or lifetime cannabis use and metabolic disorders in a cohort of 6,364 subjects infected with HCV. The study is titled Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients.
“Using cross-sectional data from the French ANRS CO22 Hepather cohort, we used regression models to test for an inverse relationship between cannabis use and (i) dyslipidemia, (ii) hypertension, and (iii) the total number of metabolic disorders”, states the study.
Continue reading
Nov 02 2022
The study was published in the journal Genes as well as on the website for the U.S. National Library of Medicine, and is titled Parent and Caregiver Perspectives towards Cannabidiol as a Treatment for Fragile X Syndrome. It was conducted by researchers at Icahn School of Medicine in New York and the National Fragile X Foundation in Virginia.
“Cannabidiol (CBD) is a non-intoxicating chemical in cannabis plants that is being investigated as a candidate for treatment in Fragile X Syndrome (FXS), a leading known cause of inherited intellectual developmental disability”, states the study’s abstract. “Studies have shown that CBD can reduce symptoms such as anxiety, social avoidance, hyperactivity, aggression, and sleep problems.”
Continue reading
Nov 01 2022
This observational open-label study “sought to investigate the effectiveness of cannabis therapy for alleviating low back pain symptoms.” The study was conducted by researchers at Tel Aviv University, the University of Haifa and Clalit Health Services. The full text of the study can be found by clicking here.
For the study two types of cannabis treatment modalities were sequentially administered to chronic low back pain patients. “After an initial 1-month washout period (WO1), the first modality was cannabidiol (CBD)-rich sublingual extract treatment administered for 10 months”, states the study.
Continue reading
Oct 29 2022
Clark County District Court Judge Joe Hardy ruled that the pharmacy board does not have the legal authority to regulate marijuana based on its status as a state-level legal substance. As such, the board must remove marijuana as a schedule 2 controlled substances, where it has been for decades (alongside crack, MDMA, LSD, PCP and others).
The Board of Pharmacy “designates a substance as a ‘controlled substance’ but the designation falls outside the authority delegated by the Legislature, the designation is invalid”, says the judge.
Continue reading